Logo image of REPL

REPLIMUNE GROUP INC (REPL) Stock Price, Quote, News and Overview

NASDAQ:REPL - Nasdaq - US76029N1063 - Common Stock - Currency: USD

8.98  -0.39 (-4.16%)

After market: 8.76 -0.22 (-2.45%)

REPL Quote, Performance and Key Statistics

REPLIMUNE GROUP INC

NASDAQ:REPL (5/30/2025, 8:00:01 PM)

After market: 8.76 -0.22 (-2.45%)

8.98

-0.39 (-4.16%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High17
52 Week Low4.93
Market Cap692.27M
Shares77.09M
Float72.57M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06
IPO07-20 2018-07-20


REPL short term performance overview.The bars show the price performance of REPL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

REPL long term performance overview.The bars show the price performance of REPL in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40 60

The current stock price of REPL is 8.98 USD. In the past month the price decreased by -6.85%. In the past year, price increased by 70.4%.

REPLIMUNE GROUP INC / REPL Daily stock chart

REPL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 328.74B
AMGN AMGEN INC 13.88 154.96B
GILD GILEAD SCIENCES INC 14.22 136.93B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.52B
REGN REGENERON PHARMACEUTICALS 11.06 52.94B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.71B
ARGX ARGENX SE - ADR 97.66 35.00B
ONC BEONE MEDICINES LTD-ADR 6.28 26.55B
BNTX BIONTECH SE-ADR N/A 23.03B
NTRA NATERA INC N/A 21.54B
BIIB BIOGEN INC 8.2 19.02B
UTHR UNITED THERAPEUTICS CORP 12.72 14.38B

About REPL

Company Profile

REPL logo image Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 331 full-time employees. The company went IPO on 2018-07-20. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. The company is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.

Company Info

REPLIMUNE GROUP INC

500 Unicorn Park Dr

Woburn MASSACHUSETTS 01801 US

CEO: Philip Astley-Sparke

Employees: 331

REPL Company Website

REPL Investor Relations

Phone: 17812229600

REPLIMUNE GROUP INC / REPL FAQ

What is the stock price of REPLIMUNE GROUP INC today?

The current stock price of REPL is 8.98 USD. The price decreased by -4.16% in the last trading session.


What is the ticker symbol for REPLIMUNE GROUP INC stock?

The exchange symbol of REPLIMUNE GROUP INC is REPL and it is listed on the Nasdaq exchange.


On which exchange is REPL stock listed?

REPL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for REPLIMUNE GROUP INC stock?

14 analysts have analysed REPL and the average price target is 22 USD. This implies a price increase of 145.02% is expected in the next year compared to the current price of 8.98. Check the REPLIMUNE GROUP INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is REPLIMUNE GROUP INC worth?

REPLIMUNE GROUP INC (REPL) has a market capitalization of 692.27M USD. This makes REPL a Small Cap stock.


How many employees does REPLIMUNE GROUP INC have?

REPLIMUNE GROUP INC (REPL) currently has 331 employees.


What are the support and resistance levels for REPLIMUNE GROUP INC (REPL) stock?

REPLIMUNE GROUP INC (REPL) has a support level at 8.34 and a resistance level at 10.02. Check the full technical report for a detailed analysis of REPL support and resistance levels.


Is REPLIMUNE GROUP INC (REPL) expected to grow?

The Revenue of REPLIMUNE GROUP INC (REPL) is expected to grow by 1897.99% in the next year. Check the estimates tab for more information on the REPL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy REPLIMUNE GROUP INC (REPL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does REPLIMUNE GROUP INC (REPL) stock pay dividends?

REPL does not pay a dividend.


When does REPLIMUNE GROUP INC (REPL) report earnings?

REPLIMUNE GROUP INC (REPL) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of REPLIMUNE GROUP INC (REPL)?

REPLIMUNE GROUP INC (REPL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.07).


What is the Short Interest ratio of REPLIMUNE GROUP INC (REPL) stock?

The outstanding short interest for REPLIMUNE GROUP INC (REPL) is 12.67% of its float. Check the ownership tab for more information on the REPL short interest.


REPL Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to REPL. When comparing the yearly performance of all stocks, REPL is one of the better performing stocks in the market, outperforming 88.57% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

REPL Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to REPL. The financial health of REPL is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

REPL Financial Highlights

Over the last trailing twelve months REPL reported a non-GAAP Earnings per Share(EPS) of -3.07. The EPS increased by 5.25% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -44.85%
ROE -59.47%
Debt/Equity 0.17
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%N/A
EPS 1Y (TTM)5.25%
Revenue 1Y (TTM)N/A

REPL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to REPL. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of 4.03% and a revenue growth 1897.99% for REPL


Ownership
Inst Owners102.71%
Ins Owners4.35%
Short Float %12.67%
Short Ratio9.83
Analysts
Analysts85.71
Price Target22 (144.99%)
EPS Next Y4.03%
Revenue Next Year1897.99%